EQ vs XNCR
EQ: A clinical-stage biotechnology company developing novel aryl hydrocarbon receptor (AhR) modulators for autoimmune and inflammatory diseases. XNCR: Xencor is a clinical-stage biopharmaceutical company leveraging its proprietary XmAb antibody engineering platform to develop innovative multi-specific therapeutics for cancer and autoimmune diseases.
Side-by-side fundamentals
| Metric | EQ | XNCR | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $2.69 | $19.53 | |
| Market cap as of 2026-07-27 | $157M | $1.3B | |
| Net margin as of 2026-07-27 | -19.6% | -177.1% | EQ higher |
| Operating margin as of 2026-07-27 | -20.1% | -222.4% | EQ higher |
| ROE as of 2026-07-27 | -61.4% | -28.8% | XNCR higher |
| ROA as of 2026-07-27 | -53.7% | -20.5% | XNCR higher |
| Debt / equity as of 2026-07-27 | 0.00 | 0.21 | EQ lower |
| Revenue growth (YoY) as of 2026-07-26 | n/a | -25.4% | |
| Revenue CAGR (3y) SEC XBRL | +61.5% | -8.6% | EQ higher |
| Beta as of 2026-07-27 | 1.87 | 0.82 | |
| 1-year return as of 2026-07-23 close | +573.0% | +110.4% | EQ higher |
Fundamentals: Finnhub, as of 2026-07-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.